Stockscreener 앱 받기
23.97
12.96%
2.75
시간 외 거래:
23.45
-0.52
-2.17%
전일 마감가:
$21.22
열려 있는:
$21.8
하루 거래량:
480.66K
Relative Volume:
12.66
시가총액:
$183.07M
수익:
-
순이익/손실:
$-61.23M
주가수익비율:
-1.773
EPS:
-13.5194
순현금흐름:
$22.49M
1주 성능:
+30.27%
1개월 성능:
+32.50%
6개월 성능:
+80.36%
1년 성능:
+79.15%
1일 변동 폭
$21.00
$23.97
1주일 범위
$17.98
$23.97
52주 변동 폭
$7.75
$23.97
Assembly Biosciences Inc Stock (ASMB) Company Profile
명칭
Assembly Biosciences Inc
전화
(833) 409-4583
주소
TWO TOWER PLACE, SOUTH SAN FRANCISCO
ASMB을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ASMB
Assembly Biosciences Inc
|
23.97 | 148.40M | 0 | -61.23M | 22.49M | -13.52 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Assembly Biosciences Inc Stock (ASMB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-25 | 개시 | Guggenheim | Buy |
| 2024-09-20 | 업그레이드 | Jefferies | Hold → Buy |
| 2021-09-13 | 개시 | H.C. Wainwright | Neutral |
| 2021-09-02 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2021-03-23 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2020-11-06 | 다운그레이드 | Jefferies | Buy → Hold |
| 2020-10-19 | 개시 | Truist | Buy |
| 2019-10-16 | 개시 | Mizuho | Buy |
| 2018-11-19 | 개시 | Leerink Partners | Outperform |
| 2018-10-08 | 업그레이드 | B. Riley FBR | Neutral → Buy |
| 2018-08-08 | 개시 | Robert W. Baird | Outperform |
| 2018-04-13 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2018-01-05 | 개시 | B. Riley FBR, Inc. | Neutral |
| 2017-11-08 | 개시 | Jefferies | Buy |
| 2017-05-30 | 개시 | Chardan Capital Markets | Buy |
모두보기
Assembly Biosciences Inc 주식(ASMB)의 최신 뉴스
Real time breakdown of Assembly Biosciences Inc. stock performanceAnnual Market Behavior and Sector Summary - Newser
Using AI based signals to follow Assembly Biosciences Inc.Swing Trade Watchlist with Entry Zones - Newser
Backtesting results for Assembly Biosciences Inc. trading strategiesBuy and Exit Strategy Based on Momentum - Newser
Can you recover from losses in Assembly Biosciences Inc.Free Trend Following Strategy With Stop Loss - Newser
Is Assembly Biosciences Inc. stock poised for growthRisk Managed Watchlist with Breakout Picks - Newser
Automated trading signals detected on Assembly Biosciences Inc.Swing Entry Insight With Forecast Accuracy - Newser
Assembly Bio’s (ASMB) HBV Drug Shows Strong Efficacy in Phase 1b Trial - MSN
What the charts say about Assembly Biosciences Inc. todayBreakout Screener With Alert Based Timing - Newser
Assembly Biosciences' ABI-5366 Demonstrates Significant Reductions in HSV-2 Shedding and Genital Lesions - AInvest
Is a relief rally coming for Assembly Biosciences Inc. holdersFree Wealth Building Stock Market Ideas - Newser
Assembly Biosciences' ABI-5366: A Catalyst for Genital Herpes Innovation and Shareholder Value - AInvest
Long term hold vs stop loss in Assembly Biosciences Inc.Real-Time Signal Tracking with Entry Level - Newser
Using fundamentals and technicals on Assembly Biosciences Inc.Risk Aware Swing Trade Analysis Insights - Newser
Assembly Biosciences: Positive Data Of ABI-5366 Brings 2 Fall Program Catalysts (ASMB) - Seeking Alpha
Assembly Bio touts Phase 1b success in herpes as Gilead buys 2.3M shares - Endpoints News
Assembly Biosciences reports positive data from herpes study - Seeking Alpha
Assembly Biosciences announces pricing of $175M in equity financings - TipRanks
Assembly Biosciences reports interim results from phase 1b study of ABI-5366 - TipRanks
Assembly Biosciences Announces Positive Phase 1b Results - TipRanks
Assembly Bio prices $130 million offering to fund viral disease research - Investing.com India
Assembly Biosciences Announces Pricing of Underwritten Registered Offering and Private Placement - Quiver Quantitative
Assembly Bio reports 94% reduction in HSV-2 shedding with new drug - Investing.com Australia
Assembly Bio reports 94% reduction in HSV-2 shedding with new drug By Investing.com - Investing.com South Africa
Assembly Biosciences raises $109.6M in underwritten, registered offering. - AInvest
Assembly Biosciences Raises $175M in Equity Financing, Gilead Sciences Invests $97M in Private Placement. - AInvest
Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Study of Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366 Showing Reductions in Viral Shedding Rate and Genital Lesion Rate in Recurrent Genital Herpes - Morningstar
Individual investors in Assembly Biosciences, Inc. (NASDAQ:ASMB) are its biggest bettors, and their bets paid off as stock gained 18% last week - simplywall.st
Historical volatility pattern of Assembly Biosciences Inc. visualizedFree Entry Points For Growing Stocks - Newser
How Resilient Is Assembly Biosciences Inc. Stock During Economic DownturnsBuy/Sell Zone Confirmation Technical Analysis - Newser
What makes Assembly Biosciences Inc. stock price move sharplySummary of Consistent Growth Stock Picks - Newser
How Efficient Is Assembly Biosciences Inc. at Controlling Operating CostsMarket Liquidity and Price Flow Analysis - Newser
Assembly Biosciences 2025 Q2 Earnings Loss Narrows with 32.8% EPS Improvement - AInvest
Assembly Biosciences (ASMB) to Release Earnings on Thursday - Defense World
Assembly Biosciences: Q2 Earnings Snapshot - New Haven Register
Order flow analysis tools used on Assembly Biosciences Inc.Growth Watchlist for Long Term Positioning - Newser
Assembly Biosciences Reports Q2 2025 Progress and Financials - TipRanks
Assembly Biosciences Reports Interim Results for ABI-6250 - TipRanks
Assembly Biosciences Reports Second Quarter 2025 Financial Results and Recent Updates - The Manila Times
Assembly Biosciences Reports Positive Phase 1b Results and Milestones for Investigational Viral Therapeutics in Q2 2025 Update - Quiver Quantitative
Assembly Biosciences Reports Interim Phase 1a Data from Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus - Stock Titan
Is Assembly Biosciences Inc. stock ready for a breakoutRapid Trade Forecast Based on Indicators - Newser
How Assembly Biosciences Inc. stock performs during market volatilityRisk Aware Trading Ideas with Alert Levels - Newser
Assembly Biosciences Inc. Stock Flags Risk Zone in Volatility IndexHigh Win Rate Trading Opportunities Detected - beatles.ru
How many analysts rate Assembly Biosciences Inc. as a “Buy”Free Trading Psychology Coaching - Jammu Links News
Does Assembly Biosciences Inc. stock perform well during market downturnsGet exclusive market analysis for investors - Jammu Links News
What are the latest earnings results for Assembly Biosciences Inc.Market-beating returns - Jammu Links News
Why is Assembly Biosciences Inc. stock attracting strong analyst attentionUnlock powerful trading tools for investors - Jammu Links News
What are Assembly Biosciences Inc. company’s key revenue driversAchieve breakthrough financial results - Jammu Links News
How does Assembly Biosciences Inc. compare to its industry peersHigh-performance stocks for savvy investors - Jammu Links News
When is Assembly Biosciences Inc. stock expected to show significant growthAchieve breakthrough financial results - Jammu Links News
Intrinsic Value of Assembly Biosciences Inc. Stock: Is It Undervalued or OvervaluedFree Smart Trade Plans With Risk Protection - Newser
Assembly Biosciences Inc (ASMB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):